Welcome to our dedicated page for Sigyn Therapeutics news (Ticker: SIGY), a resource for investors and traders seeking the latest updates and insights on Sigyn Therapeutics stock.
Sigyn Therapeutics, Inc. (OTCQB: SIGY) is a San Diego-based innovator developing blood purification technologies to combat life-threatening inflammatory conditions. This page serves as the definitive source for tracking SIGY's progress in advancing Sigyn Therapy™ and its complementary platforms targeting chemotherapy optimization and immunotherapy enhancement.
Investors and medical professionals will find timely updates on clinical milestones, regulatory developments, and strategic initiatives. Key focus areas include first-in-human studies for endotoxemia treatment, advancements in ImmunePrep™ antibody optimization, and progress toward Nasdaq listing requirements through recent corporate restructuring.
Our curated news stream covers essential updates including trial protocol finalizations, technology validation results, partnership announcements, and financial disclosures. All content is vetted for accuracy and relevance to SIGY's mission of addressing unmet needs in sepsis management, cancer care, and infectious disease treatment.
Bookmark this page for streamlined access to SIGY's evolving story in medical technology. Check regularly for developments that could influence both patient outcomes and long-term corporate valuation in this emerging therapeutic sector.
Sigyn Therapeutics (OTC: SIGY) announced the successful completion of a pilot animal study validating its Sigyn Therapy™ for treating life-threatening inflammatory conditions. This marks the first use of the therapy in mammals, demonstrating safe administration without complications over six-hour treatment periods. Sigyn Therapy aims to capture a market exceeding $20 billion annually, specifically targeting conditions like sepsis. Following positive outcomes, the company plans additional studies and seeks FDA clearance to initiate human trials.
Sigyn Therapeutics, Inc. (OTCMarkets: SIGY) announced the completion of a study demonstrating the effectiveness of Sigyn Therapy™ in eliminating hepatic toxins like bile acid, bilirubin, and ammonia from human blood plasma. Results showed an 80.6% reduction of bile acid and 55% reduction of bilirubin in one hour. The therapy targets life-threatening inflammatory conditions, especially hepatic encephalopathy, which can have a 30-day mortality rate of 38% in severe cases. The company plans to submit an Investigational Device Exemption to the FDA by year-end 2021.
Sigyn Therapeutics, Inc. (OTCMarkets: SIGY) has completed an in vitro blood purification study, validating that Sigyn Therapy can eliminate toxins associated with Hepatic Encephalopathy, a severe neurological condition. The therapy showed a 55% reduction in bilirubin levels in just one hour and 69.5% over four hours. This innovative technology addresses the significant unmet need for life-threatening inflammatory conditions. Sigyn plans to submit data for an Investigational Device Exemption to the FDA by year-end 2021, potentially expanding its market presence valued at over $20 billion.
Sigyn Therapeutics announced a webinar scheduled for June 29, 2021, at 12 PM Eastern, featuring Chairman and CEO, Jim Joyce. The webinar will cover the evolution of blood purification technologies in response to pandemic threats, including COVID-19. Joyce will discuss the significance of blood purification therapies in treating life-threatening conditions, particularly those caused by Cytokine Storm Syndrome. The company aims to address a $20 billion market opportunity with its Sigyn Therapy, designed to mitigate inflammatory conditions like sepsis.
Sigyn Therapeutics (OTCMarkets: SIGY) announced that its Chairman and CEO, Jim Joyce, will present at the LD Micro Invitational Conference on June 8, 2021, at 5:30 PM ET. The conference is focused on advancements in treating life-threatening inflammatory conditions, including sepsis, via their innovative Sigyn Therapy™. This multifaceted blood purification technology targets the Cytokine Storm, a leading cause of in-hospital deaths, with a potential market exceeding $20 billion. Details of the event will be available via a webcast.
Sigyn Therapeutics (OTCMarkets: SIGY) announced a live corporate update webinar scheduled for May 21 at 11 am ET. CEO Jim Joyce will highlight milestones in advancing Sigyn Therapy™, a blood purification technology targeting life-threatening inflammatory conditions like sepsis. Topics include team expansion, improved financial status, and upcoming studies for an Investigational Device Exemption (IDE) submission to the FDA. The company aims to address severe conditions exacerbated by cytokine storm syndrome, which significantly impacts public health.
Sigyn Therapeutics (OTCMarkets: SIGY) announced promising results from in vitro studies of Sigyn Therapy™, a technology targeting life-threatening inflammatory conditions, particularly Cytokine Storm Syndrome. The therapy demonstrated a 68.8% reduction in SARS-CoV-2 pseudotyped lentivirus after a two-hour exposure. The company highlighted a market opportunity exceeding $20 billion in addressing Cytokine Storm-related indications. Sigyn has also submitted a provisional patent application to protect its findings and plans to submit an Investigational Device Exemption to the FDA in 2021.
Sigyn Therapeutics announces its videoconference event today at 4pm Eastern, featuring Chairman and CEO Jim Joyce. This interactive session provides an opportunity for investors to discuss Sigyn Therapy™, a novel blood purification technology aimed at treating life-threatening inflammatory conditions such as cytokine storm syndrome. The event also includes analyst Rob Goldman, who has begun coverage of Sigyn Therapeutics. Space is limited; registration is available through an online link.
Sigyn Therapeutics announced that its Chairman and CEO, Jim Joyce, will participate in a roundtable forum on March 17, 2021, at 12 PM ET, hosted by Rob Goldman of Goldman Small Cap Research. The discussion will focus on Sigyn Therapy™, a blood purification technology for treating life-threatening inflammatory conditions like sepsis, which stems from Cytokine Storm Syndrome. With high mortality rates linked to conditions like COVID-19, Sigyn aims to address significant unmet medical needs. For more details, visit www.SigynTherapeutics.com.
Sigyn Therapeutics, Inc. (OTCMarkets: SIGY) announced that its Chairman and CEO, Jim Joyce, will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation will be available from March 9 at 7:00 am EST on the company’s website and during the conference. Sigyn focuses on treating life-threatening inflammatory conditions linked to Cytokine Storm Syndrome, a major cause of sepsis-related deaths. Their Sigyn Therapy aims to mitigate these conditions through novel blood purification technology.
FAQ
What is the current stock price of Sigyn Therapeutics (SIGY)?
What is the market cap of Sigyn Therapeutics (SIGY)?
